UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 68 filers reported holding UROGEN PHARMA LTD in Q1 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $157,320 | -54.7% | 15,200 | -59.6% | 0.00% | -100.0% |
| Q1 2023 | $347,424 | -23.5% | 37,600 | -26.6% | 0.00% | 0.0% |
| Q4 2022 | $454,144 | -8.4% | 51,200 | -14.1% | 0.00% | -50.0% |
| Q3 2022 | $496,000 | -19.0% | 59,600 | -20.2% | 0.00% | 0.0% |
| Q2 2022 | $612,000 | +74.9% | 74,700 | +85.9% | 0.00% | +100.0% |
| Q1 2022 | $350,000 | -41.0% | 40,192 | +32.1% | 0.00% | 0.0% |
| Q1 2021 | $593,000 | +11.3% | 30,427 | +2.9% | 0.00% | 0.0% |
| Q4 2020 | $533,000 | -20.2% | 29,569 | -14.6% | 0.00% | -50.0% |
| Q3 2020 | $668,000 | -20.9% | 34,644 | +7.2% | 0.00% | 0.0% |
| Q2 2020 | $844,000 | +55.4% | 32,324 | +6.2% | 0.00% | 0.0% |
| Q1 2020 | $543,000 | -42.1% | 30,423 | +8.3% | 0.00% | 0.0% |
| Q4 2019 | $938,000 | +40.0% | 28,100 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $670,000 | – | 28,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |